AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna

AstraZeneca Plc has sold its stake in Moderna Inc for more than $1 billion after the American biotechnology company's shares soared on the back of its coronavirus vaccine breakthrough, The Times reported.

Astrazeneca has sold its stake in Moderna for more than $1 billion: The Times

NEW YORK, Feb. 28, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AstraZeneca PLC (NASDAQ: AZN) between May 21, 2020 and November 20, 2020, inclusive (the "Class Period"), of the important March 29, 2021 lead plaintiff...

AZN BREAKING NEWS: ROSEN, TRUSTED AND TOP RANKED INVESTOR COUNSEL, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline - AZN

Amgen

AstraZeneca Plc (NASDAQ: AZN) and its partner Amgen Inc (NASDAQ: AMGN) have announced positive results from NAVIGATOR Phase 3 trial evaluating tezepelumab in severe asthma. Results were presented at the American Academy of Asthma Allergy & Immunology Annual Meeting.

AstraZeneca/Amgen's Tezepelumab Reduces Asthma Exacerbations, Phase 3 Trial Shows

LOS ANGELES, Feb. 26, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against AstraZeneca PLC ("AstraZeneca" or "the Company") (NASDAQ: AZN) for violations of §§10(b) and 20(a) of the Securities...

INVESTOR ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AstraZeneca PLC and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

New York, New York--(Newsfile Corp. - February 25, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AstraZeneca PLC (NASDAQ: AZN) between May 21, 2020 and November 20, 2020, inclusive (the "Class Period"), of the important March 29, 2021 lead plaintiff deadline.SO WHAT: If you purchased AstraZeneca securities during the Class Period you may be entitled to compensation without payment of any out of pocket...

AZN Breaking Alert: Rosen, A Leading Law Firm, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline - AZN

Bit Digital, Inc

CleanSpark

9F Inc - ADR

NEW YORK, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Bit Digital, Inc. (NASDAQ: BTBT), CleanSpark, Inc. (NASDAQ: CLSK), 9F, Inc. (NASDAQ: JFU), and AstraZeneca PLC (NASDAQ: AZN). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Bit Digital, CleanSpark, 9F, Inc., and AstraZeneca and Encourages Investors to Contact the Firm

NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against AstraZeneca PLC ("AstraZeneca" or "the Company") (NASDAQ: AZN) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired AstraZeneca securities between May 21, 2020 and November 20, 2020, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/azn. Th

AZN Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies AstraZeneca PLC Shareholders of Class Action and Encourages Shareholders to Contact the Firm

Anglo-Swedish drug company hopes to deliver 180 million doses to the 27-member bloc by June.

AstraZeneca is aiming to meet EU second-quarter COVID-19 vaccine targets, despite reports

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AstraZeneca PLC (NASDAQ: AZN) between May 21, 2020 and November 20, 2020, inclusive (the "Class Period"), of the important March 29, 2021 lead plaintiff deadline. SO WHAT: If you purchased AstraZeneca securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEX

ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline – AZN

Shares of AstraZeneca were up 0.1% in after-hours trading on Tuesday after a company executive testified before Congress that the drug maker expects to deliver 50 million of its experimental COVID-19 vaccine in the U.S. in April if it's authorized before then. That would be enough to vaccinate 25 million people.

AstraZeneca exec tells Congress it could have 50 million doses of its COVID-19 vaccine ready in April

AstraZeneca is a company going through a transformation.

AstraZeneca Growth Is Back And The Progressive Dividend Will Follow

AstraZeneca plc (NASDAQ: AZN) announced Monday a setback related to its key immuno-oncology therapy Imfinzi. What Happened: The U.K. drugmaker said it is voluntarily withdrawing Imfinzi from the U.S. market as a treatment option for previously treated adult patients with locally advanced or metastatic bladder cancer.

Why AstraZeneca Is Voluntarily Withdrawing Imfinzi In US For Advanced Bladder Cancer Indication

Shares of AstraZeneca were down 0.1% in trading on Monday after the drugmaker said it voluntarily withdrew an indication granted by the Food and Drug Administration that allows the use of Imfinzi as a treatment for certain types of bladder cancer. The FDA initally granted the company an accelerated approval in 2017 for this drug with this indication; however, the approval required additional studies, and AstraZeneca found that the drug did not meet the primary endpoints in a study conducted in 2020.

AstraZeneca to withdraw drug used to treat bladder cancer

NEW YORK, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of AstraZeneca PLC (NASDAQ: AZN) between May 21, 2020 and November 20, 2020, inclusive (the “Class Period”).

AZN MARCH 29 DEADLINE: Zhang Investor Law Alerts Investors of Deadline in Securities Class Action Lawsuit Against AstraZeneca PLC – AZN

AstraZeneca PLC (LON:AZN) announced it has voluntarily withdrawn the use of Imfinzi in patients with locally advanced or metastatic bladder cancer in the US. The decision was made in consultation with the Food and Drug Administration (FDA).

AstraZeneca withdraws bladder cancer drug in US

European healthcare workers are asking to receive other vaccine doses due to AstraZeneca's lower efficacy, and reports of negative side effects.

European Healthcare Workers Are Refusing AstraZeneca Vaccine Over Efficacy Concerns

On Saturday, the Taiwanese government granted emergency authorization for use of AstraZeneca's and Oxford University's COVID-19 vaccine, with inoculations expected to start in the next fortnight, Reuters reported. Assuming the paperwork is in order, the first shots will be distributed within a week of arrival, Food and Drug Administration Director-General Wu Shou-mei told reporters.

Taiwan grants emergency AstraZeneca COVID-19 vaccine authorization and orders 10 million doses

Johnson & Johnson

The two big drugmakers' vaccine fortunes recently went in opposite directions.

Will AstraZeneca's Pain Be Johnson & Johnson's Gain?

NEW YORK, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of AstraZeneca PLC (NASDAQ: AZN) from May 21, 2020 through November 20, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for AstraZeneca PLC investors under the federal securities laws.

AZN DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against AstraZeneca PLC– AZN

San Francisco, California--(Newsfile Corp. - February 18, 2021) - Hagens Berman urges AstraZeneca PLC (NASDAQ: AZN) investors to submit their losses now. A securities fraud class action has been filed and certain investors may have valuable claims.Class Period: May 21, 2020 - Nov. 20, 2020Lead Plaintiff Deadline: March 29, 2021Visit: www.hbsslaw.com/investor-fraud/AZNContact An Attorney Now: AZN@hbsslaw.com 844-916-0895AstraZeneca PLC (AZN) Securities Fraud Class Action:The complaint alleges that Defendants misrepresented...

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts AstraZeneca (AZN) Investors of Securities Fraud Case Related to Potential COVID-19 Treatment Filed, Filing Deadline Approaching

New York, New York--(Newsfile Corp. - February 18, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AstraZeneca PLC (NASDAQ: AZN) between May 21, 2020 and November 20, 2020, inclusive (the "Class Period"), of the important March 29, 2021 lead plaintiff deadline.SO WHAT: If you purchased AstraZeneca securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees...

Breaking News: Rosen, Globally Respected Investor Counsel, Encourages AstraZeneca PLC Investors with Large Losses to Secure Counsel Before Important Deadline - AZN

BioNTech SE

Novavax

Pfizer

As Covid-19 becomes endemic, rich governments will turn to Novavax to vaccinate people in developing economies. NVAX stock will benefit.

NVAX Stock Is the Most Undervalued Vaccine Maker for Endemic Covid-19

Alphabet

GrowGeneration Corp

Forget about the Reddit rally stocks. This trio offers far better long-term growth prospects.

3 Markedly Better Stocks to Buy Than Sundial or AMC

Merck

Based on the planned interim analysis, the Independent Data Monitoring Committee (IDMC) has recommended that OlympiA Phase 3 trial evaluating AstraZeneca Plc (NASDAQ: AZN) and Merck & Co Inc's (NYSE: MRK) Lynparza (olaparib) will move to early primary analysis and reporting. According to IDMC, the trial crossed the superiority boundary for its primary endpoint of invasive disease-free survival (iDFS).

AstraZeneca/Merck's PARP Inhibitor In Late-Stage Breast Cancer Study To Enter Early Analysis

NEW YORK, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of AstraZeneca PLC (NASDAQ: AZN) between May 21, 2020 and November 20, 2020, inclusive (the “Class Period”).

News for AstraZeneca Stock (AZN)